Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
Gene directed enzyme prodrug therapy (GDEPT) of cancer aims to improve the selectivity of chemotherapy by gene transfer, thus enabling target cells to convert nontoxic prodrugs to cytotoxic drugs. A zone of cell kill around gene-modified cells due to transfer of toxic metabolites, known as the bysta...
Main Authors: | Adam V. Patterson, Dean C. Singleton, Sophie Syddall, Michelle A. Hunt, Gabi U. Dachs |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2009-11-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/14/11/4517/ |
Similar Items
-
Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine
by: Yasuhiro Tsume, et al.
Published: (2017-08-01) -
Characteristics and efficacy of cytosine and cytidine deaminase
by: Qusay Chalabi, et al.
Published: (2007-01-01) -
Gene therapy strategies for colorectal cancer
by: Chung-Faye, Guy Allen
Published: (2002) -
Characterization and Cytotoxic Activity of Cytosine Deaminase Enzyme Purified from Locally Isolated Escherichia coli
by: Baghdad Science Journal
Published: (2018-09-01) -
Effectiveness of the enzyme cytosine deaminase in the free living ciliary organism Tetrahymena pyriformis (Ehrenberg, 1830)
by: Zahraa Bashi, et al.
Published: (2008-09-01)